Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH trial in rheumatoid arthritis after failure of an initial TNF blocker
2010-023880-17Phase 4Completed
- Sponsor
- University of Leeds
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab, abatacept, infliximab, etanercept, adalimumab and 2 more in rheumatoid arthritis (RA) (3 arms), sponsored by University of Leeds. Primary endpoint: Change in Disease Activity Score 28. Started Feb 2011; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-023880-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023880-17.